SNGX News and Press, Soligenix Inc. From 03/09/23

Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N....

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: T. Schneider / Shutterstock.com Occidental Petroleum (NYSE: OXY ) stock is on the rise Tuesday following an upgrade from Goldman Sachs. Goldman Sachs analyst Neil Mehta is behind today’s upgrade, wh...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Soligenix (NASDAQ: SNGX ) stock is falling hard on Tuesday after the company’s HyBryte cancer drug was declined for review by the U.S. Food and Drug Administration (FDA). ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Soligenix (NASDAQ: SNGX ) stock is falling hard on Tuesday after the company’s HyBryte cancer drug was rejected by the FDA. The FDA is refusing to review an application...

The U.S. Food and Drug Administration (FDA) declined to accept for review Soligenix's ( NASDAQ: SNGX ) new drug application (NDA) seeking approval of HyBryte (synthetic hypericin) to treat early stage cutaneous T-cell lymphoma (CTCL). The FDA provided the company with a Refusal t...

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Soligenix intends to seek guidance from the FDA on how to further advance HyBryte ™ towards potential...

Soligenix ( NASDAQ: SNGX ) plans to execute a reverse stock split of its common stock, effective at 4:00 p.m. on February 9, 2023. At the effective time of the reverse stock split, every 15 shares of Soligenix's ( SNGX ) issued and outstanding common stock will be converted au...

Soligenix Announces Reverse Stock Split PR Newswire Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J. , Feb. 9, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company),...

Soligenix Invited to Present at the Virtual Investor Summit Event PR Newswire Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix,...

Company Seeks Approval for Reverse Stock Split to Maintain Nasdaq Listing   NEW YORK, NY - ( NewMediaWire ) - January 12, 2023 - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX) is on track to deliver a safe and effective front-line treatment to ...